Clinical trial
Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C…
NCT00351403 · FGK Clinical Research GmbH, Industry · Completed
Key facts
| NCT number | NCT00351403 |
|---|---|
| Title | Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection |
| Official title | Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA |
| Lead sponsor | FGK Clinical Research GmbH, Industry |
| Collaborators | University Hospital, Saarland |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Ribavirin, Peginterferon alfa 2b |
| Enrollment | 390 |
| Start date | Jul 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Jul 12, 2006 |
| Last update posted | Feb 8, 2010 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: